Tehran University of Medical Sciences Journal of Pharmaceutical Care 2322-4630 4 3-4 2018 02 03 79 85 EN Hamidreza Taghva Masoumi Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran Molouk Hajibabaie Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran AND Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran Kheirollah Gholami Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran AND Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran Maryam Shahrokhi Clinical Pharmacy Department, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran 2016 12 17 2017 04 08 Invasive fungal infections are one of important complication in patients receiving chemotherapy or hematopoietic stem cell transplantation. Voriconazole is a triazole antifungal agent widely used for prophylaxis and treatment of fungal infections. It is also administered for empiric treatment of fungal infections in patients with febrile neutropenia. Although amphotericin B preparations and fluconazole generally are used for empiric antifungal therapy and antifungal prophylaxis, but it should be noted that there are insufficient data to draw any firm conclusion about use of other new alternatives as drug of choice. This paper will review the researches that conducted on voriconazole as an empiric antifungal therapy or antifungal prophylaxis in patients with neutropenia following chemotherapy or HSCT. https://jpc.tums.ac.ir/index.php/jpc/article/view/133 https://jpc.tums.ac.ir/index.php/jpc/article/download/133/110